Cargando…
Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer
Non-small cell lung cancer (NSCLC) accounts for 80–85% of lung cancer cases, and almost half of newly diagnosed patients have metastatic disease. Pemetrexed is a widely used drug for NSCLC and inhibits several folate-dependent enzymes including thymidylate synthase (TS). Increased expression of TS c...
Autores principales: | Kawabata, Shigeru, Chiang, Chun-Te, Tsurutani, Junji, Shiga, Hideaki, Arwood, Matthew L., Komiya, Takefumi, Gills, Joell J., Memmott, Regan M., Dennis, Phillip A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011583/ https://www.ncbi.nlm.nih.gov/pubmed/24658085 |
Ejemplares similares
-
Rapamycin sensitizes cancer cells to growth inhibition by the PARP inhibitor olaparib
por: Osoegawa, Atsushi, et al.
Publicado: (2017) -
Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma
por: YANG, MIN, et al.
Publicado: (2014) -
Thymidylate Synthase as a Predictive Biomarker for Pemetrexed Response in NSCLC
por: Bukhari, Ali A., et al.
Publicado: (2013) -
Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural Mesothelioma
por: Sato, Yuzo, et al.
Publicado: (2021) -
High pemetrexed sensitivity of docetaxel-resistant A549 cells is mediated by TP53 status and downregulated thymidylate synthase
por: Kuo, Wei-Ting, et al.
Publicado: (2017)